New ulcerative colitis drug enters first human safety tests
Disease control
Not yet recruiting
This early-stage study tests the safety of a new drug called LYNC-101 in 50 healthy adults. The drug is being developed to control ulcerative colitis, a chronic bowel disease. Participants receive one or three intravenous infusions and are monitored for side effects. This study d…
Phase: PHASE1 • Sponsor: LyncBio Therapeutics Co., Ltd. • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC